First Quarter 2012 Financial Results Conference Call
May 3, 2012
First Quarter 2012 Financial Results Conference Call May 3, 2012 - - PowerPoint PPT Presentation
First Quarter 2012 Financial Results Conference Call May 3, 2012 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to,
May 3, 2012
1
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding the closing of pending transactions, expected revenue and synergies, product approvals and launches and financial guidance for 2012. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,”
those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. Non-GAAP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, stock- based compensation step-up, restructuring and acquisition-related costsTBD, acquired in-process research and development ("IPR&D"), legal settlements, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, and (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core
GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
Note 1: The guidance in this presentation is only effective as of the date given, May 3, 2012, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.
2
3
Q1 2011* Q1 2012* Q1 2012 vs 2011 Product Sales $500 M $768 M 54% Cash EPS $0.56 $0.99 77% Adjusted Cash Flow $204 M $255 M 25%
*First quarter 2011 excludes $36 M from the out-license of Cloderm and first quarter of 2012 excludes $66 M from divestiture of
IDP-111 and generic Efudex
4
Organic Growth
24%
22% 12%
First Quarter 2012
Emerging Markets Canada/ Australia U.S Neurology & Other U.S Dermatology
Total Company Organic Growth 11%
5
Announced YTD 2012
Probiotica (Brazil) – Closed EyeTech (U.S.) – Closed Pele Nova (Brazil) – Closed Pedinol (U.S.) – Closed Natur Produkt (Russia) – (Expected to Close mid-year) Gerot Lannach (Russia) – Closed Atlantis (Mexico) – (Expected to Close 2Q12) AcneFree (U.S.) – (Expected to Close mid-year)
Other transactions
Divested Bioskin Acquired assets - Ortho Dermatologics – Canada Acquired assets – Ortho Dermatologics - Brazil
Total Purchase Price = ~$600 million Expected 2012 Revenue Run Rate = ~$280 million Sales Multiple Paid = ~2.1 X
6
Run rate expected by mid-year Run Rate
May 3, 2012
$200 million $165 million
Run Rate
Feb 23, 2012
$135 million
Run rate expected by Year-end
$230+ million*
* Includes acquisitions announced and closed in 2012
7
(After deals closed)
Brazil Mexico Latin America All Other Serbia Russia Central/Eastern Europe Poland South Africa Thailand Malaysia Philippines South East Asia/South Africa Export Asia - Other
Additional Updates:
~$350M ~$100M ~$750M
9
Q1 2012 Net Sales Q1 2012 vs. Q1 2011
Wellbutrin XL Cardizem CD Ultram ER Core Neuro & Other
Total
All Other Wellbutrin XL Cardizem CD Ultram ER Total
$48M $135M $183M
6% (10)% (37)%
10
2012 vs. 2011 Volume Growth (MAT)
Source: Wolters Kluwer Health; IRI Scan data; Retailer data 37% 38% 28% 12%
0% 10% 20% 30% 40% 50% 60% 70% Acanya* Atralin Zovirax** CeraVe***
*Acanya impacted by unusually high March 2011 TRx volume **Zovirax volume in TRx grams ***CeraVe scan volume growth
11
Source: Wolters Kluwer Health
Market Growth 2012 vs. 2011 Q1 2012 March 2012 Topical Calcineurin Inhibitors (Derm only) – e.g., Elidel 6.9% (0.2%) Fixed Dose Acne Combo (BPO / Clindamycin) – e.g., Acanya (4.5%) (10.6%) Tretinoins – e.g., Atralin 5.6% (3.9%) Anti-Viral – e.g., Zovirax 3.9% (0.4%)
12
Canada
Product Launches
Lodalis; Sublinox
Generic competition for Cesamet
U.S. Neuro & Other
Potiga U.S. launch
U.S. Dermatology
IDP-108 Update
14
Q1 2011* Q2 2011 Q3 2011 Q4 2011 Q1 2012* Product Sales $500M $530M $570M $654M $790M Total Revenue $565M $609M $601M $688M $856M Cost of Goods Sold% 27% 29% 28% 25% 26% SGA% 21% 22% 21% 21% 19% R&D Expense $14M $18M $18M $17M $22M Operating Margin 50% 53% 50% 57% 55% (excluding amortization) Cash EPS $0.62 $0.73 $0.66 $0.94 $1.14 Adjusted Cash Flow from Operations $204M $260M $208M $253M $322M Fully Diluted Share Count 333 M 331 M 323 M 317 M 316 M
* Includes out-licensce of Cloderm in Q1’11 and divestiture of dermatology products in Q2’12
15
38% 27% 12% 23%
Neuro Derm Canada / Australia Emerging Markets
U.S. ~52% U.S. ~65%
24% 28% 17% 31%
16
Sequential increase due to:
Increased Canada contract manufacturing
Product Mix (U.S. & Europe)
Unfavorable Exchange Rates (Europe)
Delayed plant consolidations
* COGS based on product sales only
Q4’11 Q1’12 U.S. Neuro 17% 18% U.S. Derm 11% 10% Can/Aus 23% 26% Emerg Mkts 42% 47% Total COGS 25% 26%
17
$164 $322 $350 $113 $302 $11 $87 $8 $330
Cash December 2011 Securities Repurchases Acquisitions Cap Ex Restructuring/ Integration/ Legal Settlements Other2 Cash March 2012 Net Issuance LT Debt Adjusted CashFlow from Operations1
2Includes payment of withholding tax upon vesting of share based awards, one-time working capital adjustments, proceeds from the
exercise of stock options and other miscellaneous cash outflows
1Includes impact of divestiture of IDP-111 and 5FU
18
FX Impact
Resulted in a ~$20 million reduction to revenue
Working Capital Improvement
Improved from 35% of LTM revenue in Q4 11 to 30% of LTM revenue in Q1 12 Inventory increased vs Q4 due to stock build related to tech transfers (Brazil,
U.S.)
Securities Repurchase Program
Repurchased over 2 million common shares for an aggregate purchase
price of $108.7 million
316 million fully diluted share count as of March 31, 2012
Currency Poland Serbia Hungary Russia Australia Canada Mexico Brazil South Africa Q1’11 vs Q1’12
5%
20
Revenue $3.1 - $3.4 billion
$3.95 - $4.20 Adjusted Cash EPS
> $1.2 billion in Adjusted Cash Flow from Operations
Revenue > $3.4 - 3.6 billion
$4.45 - $4.70 Adjusted Cash EPS
> $1.4 billion in Adjusted Cash Flow from Operations
See Note 1 regarding guidance
May 3, 2012